Abstract
More than 80 sleep disorders have been identified. They affect over 200
million people worldwide. The report focuses on the market for following sleep
disorders:
- Insomnia
- Restless legs syndrome (RLS)
- Narcolepsy and
- Obstructive Sleep Apnoea / Hypopnea Syndrome (OSAHS)
The market penetration for insomnia drugs has not reached saturation point.
Opportunities remain. But with the introduction of several new products the
market is set to see changes, but expansion. This expansion is based on
increased general awareness physicians better comprehension of the
significance of this disease and the positive role that a sleep medication
prescription plays.
At present time there are several prescription sleeping medications available
to treat insomnia. The market-focus has been driven by the production of sleep
medications with less side-effects and danger of overdose. Prescription
benzodiazepines and newer non-benzodiazepine hypnotics developed in the 1990s,
such as Imovane, Ambien and Sonata will continue to be the most prescribed.
Benzodiazepines are widely used to treat an underlying neurological disorder
which is often the underlying cause of insomnia, e.g. anxiety and depression.
Visiongain predicts that market share by volume for insomnia in the US will
change significantly from 2008 to 2018. Ambien IR lost its patent protection
in April 2007, which opened to generic competition for Zolpidem. Ambien will
remain the market leader for the short term, but what will over take it? A
generic version of Ambien is expected to achieve strong market share by volume
as there is a great demand for zolpidem tartrate for insomnia.
The market share for insomnia treatment will gradually rise after 2012, which
will be due to:
- Market expansion of existing expensive medications into Europe and Japan
in particular
- Market penetration of new medications currently in pipeline.
Other drugs dealt with in this report include:
- - Modafinil (Provigil) is the first in a new class of wake-promoting drugs
and is currently approved in more than 20 countries for the treatment of
excessive daytime sleepiness associated with narcolepsy. Provigil is quickly
replacing Ritalin, and other CNS stimulants, as the medication of choice for
treating daytime sleepiness in narcolepsy. The FDA granted modafinil
(Provigil) orphan drug status in 1993. Modafinil was initially launched in
the US in 1999 for the treatment of narcolepsy. In 2004, modafinil became
FDA-approved prescription medicine for the treatment of excessive sleepiness
associated with Obstructive Sleep Apnoea/Hypopnea Syndrome (OSAHS) and Shift
Workers Sleep Disorder (SWSD).
- - Requip (ropinirole) became the first and only FDA-approved drug
treatment for moderate to severe primary Restless Legs Syndrome (RLS) in 2005.
Key findings that will broaden the scope of the sleep disorders market:
- Over the next decade, the development and improvement of sleep disorders
therapies will primarily depend on the success of burgeoning technology and
innovative approaches.
- It is possible to purchase prescription medications online without
producing a prescription. Purchase of online sleep medications has increased
and will continue to evolve over the next years.
- The impact of DTC advertising has created an improved awareness of
available insomnia treatment. This is likely to increase as DTC advertising
continues to prosper and the culture becomes more accepting towards insomnia
treatment. Visiongain expects the market for sleep disorders to increase,
driven by a growing awareness of sleep disorders and by campaigns to promote
sleep medications, both by DTC advertising and consumer education. The
relaxation of DTC marketing restrictions in the 1990s in the US set the stage
for a flow for both branded and unbranded advertising and promotional
programmes. Those regulations are prompting more responsible DTC advertising
on the industry' s part.
- The FDA has requested that all manufacturers of sedative-hypnotic drug
products, a class of drugs used to induce and/or maintain sleep, strengthen
their product labelling to include stronger warnings concerning potential
risks.
- The Committee for Medicinal Products in Human Use (CHMP) of the European
Medicines Agency (EMEA) approved Neurim' s Circadin a prolonged-release
melatonin as monotherapy for the short-term treatment of primary insomnia
characterised by poor quality of sleep in patients aged 55 or over. Neurim is
actively seeking strategic alliances for the major European markets.
What questions does the report answer?
- Which current or future therapies will drive the sleep disorders market
from 2008 to 2018?
- The key companies involved in the market and their analysis?
- What is the patient identification rate for each of the therapeutic areas?
- What is the present state of the disease awareness?
- What R&D opportunities exist for ' new comers' ?
Why should you buy this report?
- This report focuses on the marketed medications and the pipeline
development for sleep disorders from 2008 to 2018. It also discusses the
strength and weakness of products, along with the opportunities and threats
facing the market.
- The report describes world market situation for sleep disorders, namely
insomnia, narcolepsy, RLS and OSAHS, with forecasts made for all key products.
It also describes the insomnia market situation in the seven major world
markets for sleep medications: the US, Japan, France, Germany, Italy, Spain
and the UK, with forecasts for key products.
- The report provides transcripts of visiongain' s interviews with experts in
the field of sleep disorders, which reviews the future direction of the sleep
disorders treatment market.
Unique benefits to you when you order this report
- - You can access your report whichever country you are in without using
harddrive space
- - Primary research throughout. You will not find this information anywhere
else
- - Full searchable report when you buy the company or corporate editions
- - Copies can be printed off for offline reading
- - Packed with charts, analysis, figures, graphs and tables
View Cart
